Dovato Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Dovato Availability in 2026

If your patients have been reporting difficulty filling their Dovato prescriptions, they're not imagining things. While Dovato (Dolutegravir 50 mg/Lamivudine 300 mg) is not listed on the FDA's drug shortage database as of early 2026, real-world availability at retail pharmacies remains inconsistent.

This article provides a clinical and logistical overview to help providers understand the current landscape, counsel patients effectively, and leverage tools that streamline access.

Timeline: How We Got Here

Dovato received FDA approval in April 2019 as the first complete two-drug regimen for treatment-naive adults with HIV-1. Manufactured by ViiV Healthcare, it offered a simplified alternative to three-drug regimens — one pill, once daily, with a favorable side effect profile.

Since launch, Dovato has gained a solid share of new HIV treatment initiations, particularly among patients and providers looking to minimize NRTI exposure. However, its specialty status and the dominance of Biktarvy in the market have meant that not all pharmacies maintain adequate inventory.

Key milestones:

• April 2019: FDA approval for treatment-naive adults
• 2020: Expanded indication to include virologically suppressed patients switching from a stable regimen
• 2021–2025: Gradual uptake, particularly in specialty and academic settings
• 2026: No formal shortage, but persistent retail availability challenges

Prescribing Implications

The availability landscape has several practical implications for prescribers:

Prior Authorization Burden

Many commercial and Medicare Part D plans require prior authorization for Dovato, particularly when the formulary preference is for Biktarvy or another three-drug STR. This adds administrative burden and can delay treatment initiation or continuation.

Recommendation: When initiating Dovato, submit prior authorization proactively at the time of prescribing rather than waiting for a pharmacy rejection. Many EHR systems support electronic prior auth submission.

Resistance Considerations for Switching

For patients currently suppressed on Dovato who face access issues, a switch to an alternative regimen should be guided by:

• Historical resistance testing results
• HLA-B*5701 status (if considering Triumeq)
• Hepatitis B co-infection status (Lamivudine discontinuation requires HBV monitoring)
• Current and anticipated drug-drug interactions
• Patient preference regarding pill burden, injectable options, etc.

For a patient-facing overview of alternatives, see our alternatives to Dovato guide.

Hepatitis B Monitoring

Dovato contains Lamivudine, which has activity against HBV. The product carries a boxed warning regarding severe acute exacerbations of hepatitis B upon discontinuation. If a co-infected patient must switch away from Dovato, ensure appropriate HBV coverage is maintained and monitor hepatic function closely.

Current Availability Picture

The following patterns characterize Dovato availability in 2026:

• Specialty pharmacies: Generally reliable stock; these remain the most consistent source
• Large chain pharmacies (CVS, Walgreens, Rite Aid): Variable. Many locations carry Biktarvy as their primary INSTI-based STR and may not stock Dovato
• Independent pharmacies: Some HIV-focused independents stock Dovato reliably; others do not
• Mail-order/specialty mail: Consistent availability; recommended for patients with ongoing access challenges
• 340B pharmacies: Availability depends on the covered entity's formulary decisions

Cost and Access Considerations

Understanding the cost structure helps when counseling patients:

• WAC (wholesale acquisition cost): Approximately $2,400/month
• Cash price at retail: $2,000–$2,800/month
• ViiV copay savings card: Reduces commercial copay to as low as $0/month (not valid for government insurance)
• ViiV Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients (income-based eligibility)
• ADAP coverage: Available in all states, though formulary placement varies
• 340B pricing: Significant discounts for eligible covered entities

For detailed cost information to share with patients, direct them to our savings guide for Dovato.

Tools and Resources for Providers

Several tools can help you and your patients navigate availability challenges:

Medfinder for Providers

Medfinder offers a provider-facing tool that allows your team to check real-time pharmacy stock for Dovato and other medications. This can be integrated into your workflow when writing prescriptions — verify stock before sending the Rx to a pharmacy, reducing patient frustration and call-backs.

ViiV Connect

ViiV Healthcare's patient support program (1-844-588-3288) assists with:

• Locating pharmacies with Dovato in stock
• Copay savings card enrollment
• Patient assistance program applications
• Prior authorization support

HRSA/Ryan White Resources

For patients enrolled in Ryan White-funded care, case managers can often facilitate access through their pharmacy networks. The ADAP formulary in your state will determine Dovato coverage.

Looking Ahead

Several developments may impact Dovato access in the coming months and years:

• Generic availability: No generic Dovato is expected in the near-term U.S. market. Lamivudine is available generically, but the combination tablet remains patent-protected.
• Long-acting alternatives: Cabenuva (Cabotegravir/Rilpivirine) and future long-acting formulations offer an alternative pathway for patients struggling with oral medication access.
• Lenacapavir combinations: Emerging long-acting agents like Lenacapavir may expand the treatment landscape further.
• Policy changes: Ongoing discussions around PBM reform, specialty drug tiers, and 340B policy could impact access and affordability.

Final Thoughts

Dovato remains an excellent two-drug regimen with strong clinical evidence and a favorable safety profile. The availability challenges facing patients are largely logistical, not supply-driven. As providers, we can help by:

• Proactively submitting prior authorizations
• Directing patients to specialty pharmacies and mail-order options
• Using tools like Medfinder to verify stock before prescribing
• Connecting patients with ViiV's support programs
• Monitoring HBV co-infection status closely during any transitions

For practical workflow tips on helping your patients access Dovato, see our companion guide: How to Help Your Patients Find Dovato in Stock.